Solid-State Chemistry: A Technical Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Chemistry: A Technical Forum
Leading experts share insight on polymorphism and crystallization.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 34-35, 65

References

1. ICH, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (1999).

2. H.G. Brittain, Ed., Polymorphism in Pharmaceutical Solids (2nd edition, Informa Healthcare, London).

3. J. Haleblian and W. McCrone, J. Pharm. Sci., 58 (58), 911–929 (1969).

4. T.L. Threlfall, Analyst, 120 (10) 2435–2460 (1995).

5. D. Singhal D and W. Curatolo, Adv. Drug Delivery Rev. 56 (5) 335–347 (2004).

6. S.L. Price, Acc. Chem. Res. 42 (1) 117–126 (2009).

7. M.A. Neumann and M.A. Perrin, J. Phys. Chem. B, 109 (32), 15531–15541 (2005).

8. M.A. Neumann, J. Phys. Chem. B, 112 (32), 9810–9829 (2008).

9. M.A. Neumann, F.J.J. Leusen, and J. Kendrick, Angew. Chem. Int. Ed. 47 (13), 2427–2430 (2008).

10. G.M. Day et al., Acta Cryst. B 65 (2) 107–125 (2009).

11. S.R.Chemburkar et al., Org. Process Res. Dev. 4 (5), 413–417 (2000).

12. Y. Kobayashi et al., "Int. J. Pharm 193 (2), 137–146 (2000).

13. J. Aaltonen et al., Eur. J. Pharm. Biopharm. 71 (1), 23–37 (2009).

For additional insight on screening strategies in solid-state chemistry, see http://pharmtech.findpharma.com/pharmtech/Ingredients/Polymorph-Screening-Strategies-A-QampA-with-Jan-Ol/ArticleStandard/Article/detail/647428.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here